These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24381243)

  • 61. Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder.
    Thase ME; Gommoll C; Chen C; Kramer K; Sambunaris A
    Int Clin Psychopharmacol; 2016 Nov; 31(6):332-40. PubMed ID: 27455513
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results.
    Kasper S; Pletan Y; Solles A; Tournoux A
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():35-9. PubMed ID: 8923125
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data.
    Mease PJ; Zimetbaum PJ; Duh MS; Vekeman F; Guérin A; Boerstoel-Streefland M; Jiang W; Lefebvre P
    Ann Pharmacother; 2011 Feb; 45(2):179-88. PubMed ID: 21304035
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder.
    Gommoll CP; Greenberg WM; Chen C
    J Drug Assess; 2014; 3(1):10-9. PubMed ID: 27536449
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Chronic effects of antidepressants on serotonin release in rat raphe slice cultures: high potency of milnacipran in the augmentation of serotonin release.
    Nagayasu K; Kitaichi M; Nishitani N; Asaoka N; Shirakawa H; Nakagawa T; Kaneko S
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2295-306. PubMed ID: 23920436
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of repeated milnacipran administration on brain serotonergic and noradrenergic functions in healthy volunteers.
    Soya A; Terao T; Nakajima M; Kojima H; Okamoto T; Inoue Y; Iwakawa M; Shinkai K; Yoshimura R; Ueta Y; Nakamura J
    Psychopharmacology (Berl); 2006 Sep; 187(4):526-7. PubMed ID: 16830129
    [No Abstract]   [Full Text] [Related]  

  • 67. Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder.
    Perry R; Cassagnol M
    Clin Ther; 2009 Jun; 31 Pt 1():1374-404. PubMed ID: 19698900
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.
    Papakostas GI; Fava M
    Eur Neuropsychopharmacol; 2007 Jan; 17(1):32-6. PubMed ID: 16762534
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Agomelatine versus other antidepressive agents for major depression.
    Guaiana G; Gupta S; Chiodo D; Davies SJ; Haederle K; Koesters M
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD008851. PubMed ID: 24343836
    [TBL] [Abstract][Full Text] [Related]  

  • 70. In vivo canine model comparison of cardiovascular effects of antidepressants milnacipran and imipramine.
    Mitsumori Y; Nakamura Y; Hoshiai K; Nagayama Y; Adachi-Akahane S; Koizumi S; Matsumoto M; Sugiyama A
    Cardiovasc Toxicol; 2010 Dec; 10(4):275-82. PubMed ID: 20680703
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L
    J Affect Disord; 2016 May; 196():225-33. PubMed ID: 26938965
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy and tolerability of milnacipran: an overview.
    Montgomery SA; Prost JF; Solles A; Briley M
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():47-51. PubMed ID: 8923127
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran.
    Wakeno M; Kato M; Okugawa G; Fukuda T; Hosoi Y; Takekita Y; Yamashita M; Nonen S; Azuma J; Kinoshita T
    J Clin Psychopharmacol; 2008 Oct; 28(5):518-24. PubMed ID: 18794646
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Milnacipran: a dual norepinephrine and serotonin reuptake pump inhibitor.
    Preskorn SH
    J Psychiatr Pract; 2004 Mar; 10(2):119-26. PubMed ID: 15330407
    [No Abstract]   [Full Text] [Related]  

  • 75. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran.
    Yoshida K; Higuchi H; Takahashi H; Kamata M; Sato K; Inoue K; Suzuki T; Itoh K; Ozaki N
    Hum Psychopharmacol; 2008 Mar; 23(2):121-8. PubMed ID: 18023073
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?
    Wong DT; Bymaster FP
    Prog Drug Res; 2002; 58():169-222. PubMed ID: 12079200
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Reboxetine: a norepinephrine selective reuptake pump inhibitor.
    Preskorn SH
    J Psychiatr Pract; 2004 Jan; 10(1):57-63. PubMed ID: 15334987
    [No Abstract]   [Full Text] [Related]  

  • 78. Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.
    Nichols AI; Tourian KA; Tse SY; Paul J
    Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1565-74. PubMed ID: 21067460
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A comparative study of milnacipran and paroxetine in outpatients with major depression.
    Sechter D; Vandel P; Weiller E; Pezous N; Cabanac F; Tournoux A;
    J Affect Disord; 2004 Dec; 83(2-3):233-6. PubMed ID: 15555719
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
    Papakostas GI; Thase ME; Fava M; Nelson JC; Shelton RC
    Biol Psychiatry; 2007 Dec; 62(11):1217-27. PubMed ID: 17588546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.